528 related articles for article (PubMed ID: 33048929)
21. Estimating the impact of a police education program on hepatitis C virus transmission and disease burden among people who inject drugs in Tijuana, Mexico: A dynamic modeling analysis.
Rivera Saldana CD; Abramovitz D; Beletsky L; Borquez A; Kiene S; Marquez LK; Patton T; Strathdee S; Zúñiga ML; Martin NK; Cepeda J
Addiction; 2023 Sep; 118(9):1763-1774. PubMed ID: 37039246
[TBL] [Abstract][Full Text] [Related]
22. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study.
Uyei J; Fiellin DA; Buchelli M; Rodriguez-Santana R; Braithwaite RS
Lancet Public Health; 2017 Mar; 2(3):e133-e140. PubMed ID: 29253386
[TBL] [Abstract][Full Text] [Related]
23. The cost-effectiveness of Vancouver's supervised injection facility.
Bayoumi AM; Zaric GS
CMAJ; 2008 Nov; 179(11):1143-51. PubMed ID: 19015565
[TBL] [Abstract][Full Text] [Related]
24. Gender-specific participation and outcomes among jail diversion clients with co-occurring substance use and mental health disorders.
Robertson AG; Easter MM; Lin HJ; Khoury D; Pierce J; Swanson J; Swartz M
J Subst Abuse Treat; 2020 Aug; 115():108035. PubMed ID: 32600621
[TBL] [Abstract][Full Text] [Related]
25. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky.
Stone J; Fraser H; Young AM; Havens JR; Vickerman P
Int J Drug Policy; 2021 Feb; 88():102707. PubMed ID: 32151496
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.
Mozaffarian D; Liu J; Sy S; Huang Y; Rehm C; Lee Y; Wilde P; Abrahams-Gessel S; de Souza Veiga Jardim T; Gaziano T; Micha R
PLoS Med; 2018 Oct; 15(10):e1002661. PubMed ID: 30278053
[TBL] [Abstract][Full Text] [Related]
27. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.
Mafirakureva N; Stone J; Fraser H; Nzomukunda Y; Maina A; Thiong'o AW; Kizito KW; Mucara EWK; González Diaz CI; Musyoki H; Mundia B; Cherutich P; Nyakowa M; Lizcano J; Chhun N; Kurth A; Akiyama MJ; Waruiru W; Bhattacharjee P; Cleland C; Donchuk D; Luhmann N; Loarec A; Maman D; Walker J; Vickerman P
Addiction; 2022 Feb; 117(2):411-424. PubMed ID: 34184794
[TBL] [Abstract][Full Text] [Related]
28. Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective.
van Santen DK; Coutinho RA; van den Hoek A; van Brussel G; Buster M; Prins M
Harm Reduct J; 2021 Jan; 18(1):2. PubMed ID: 33407562
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
30. Is your syringe services program cost-saving to society? A methodological case study.
Des Jarlais DC; Feelemyer J; McKnight C; Knudtson K; Glick SN
Harm Reduct J; 2021 Dec; 18(1):126. PubMed ID: 34876135
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of drug consumption rooms in France: a modelling study.
Cousien A; Donadille C; Madrid LB; Maradan G; Jauffret-Roustide M; Lalanne L; Auriacombe M; Roux P; Boyer S
BMC Public Health; 2024 May; 24(1):1426. PubMed ID: 38807111
[TBL] [Abstract][Full Text] [Related]
32. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z; Scott N; Nayagam S; Rwegasha J; Mbwambo J; Thursz MR; Brown AS; Hellard M; Lemoine M
Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands.
Helsper CW; Janssen MP; van Essen GA; Croes EA; van der Veen C; de Wit AG; de Wit NJ
Int J Drug Policy; 2017 Sep; 47():117-125. PubMed ID: 28826994
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of brief and expanded evidence-based risk reduction interventions for HIV-infected people who inject drugs in the United States.
Song DL; Altice FL; Copenhaver MM; Long EF
PLoS One; 2015; 10(2):e0116694. PubMed ID: 25658949
[TBL] [Abstract][Full Text] [Related]
36. Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations.
Moreno GA; Wang A; Sánchez González Y; Díaz Espinosa O; Vania DK; Edlin BR; Brookmeyer R
Value Health; 2017 Jun; 20(6):736-744. PubMed ID: 28577690
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of a police education program on HIV and overdose among people who inject drugs in Tijuana, Mexico.
Cepeda JA; Beletsky L; Abramovitz D; Saldana CR; Kahn JG; Bañuelos A; Rangel G; Arredondo J; Vickerman P; Bórquez A; Strathdee SA; Martin NK
Lancet Reg Health Am; 2024 Feb; 30():100679. PubMed ID: 38327278
[TBL] [Abstract][Full Text] [Related]
38. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
[TBL] [Abstract][Full Text] [Related]
39. Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model.
Scott N; Mohamed Z; Rwegasha J; Mbwambo J; Lemoine M; Hellard M
Int J Drug Policy; 2021 Feb; 88():102634. PubMed ID: 31882272
[TBL] [Abstract][Full Text] [Related]
40. The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.
Hood JE; Behrends CN; Irwin A; Schackman BR; Chan D; Hartfield K; Hess J; Banta-Green C; Whiteside L; Finegood B; Duchin J
Int J Drug Policy; 2019 May; 67():9-18. PubMed ID: 30802842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
